Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 1971 to 1980 of 2610 total matches.
Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 10, 2022 (Issue 1641)
Table 1). They are the first
drugs to be authorized by the FDA for this indication.1
Two other pairs ...
The FDA has issued an Emergency Use Authorization
(EUA) for the investigational long-acting monoclonal
antibodies tixagevimab and cilgavimab (Evusheld –
AstraZeneca) to be administered concomitantly by IM
injection for pre-exposure prophylaxis of COVID-19 in
persons ≥12 years old who weigh ≥40 kg and have
either a history of severe allergy that prevents their
vaccination against COVID-19 or moderate or severe
immune compromise (see Table 1). They are the first
drugs to be authorized by the FDA for this indication.
Two other pairs of antibodies, bamlanivimab plus
etesevimab...
Comparison Chart: Correct Use of Inhalers for Asthma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
inhaler
▶ Drug delivery to the lungs is dependent upon ability to perform a rapid, deep
inhalation ...
View the Comparison Chart: Correct Use of Inhalers for Asthma
Med Lett Drugs Ther. 2024 Nov 25;66(1716):e196-8 doi:10.58347/tml.2024.1716c | Show Introduction Hide Introduction
Palopegteriparatide (Yorvipath) for Hypoparathyroidism
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025 (Issue 1726)
, and diarrhea.
▶ Drug Interactions: Hypocalcemia could reduce the efficacy
of digoxin, and hypercalcemia ...
Palopegteriparatide (Yorvipath – Ascendis), a parathyroid
hormone (PTH) 1-34 analog, has been approved
by the FDA for treatment of hypoparathyroidism in
adults. The parathyroid hormone analog teriparatide
(Forteo, and others), which is approved for treatment
of postmenopausal osteoporosis, has been used off-label
for treatment of hypoparathyroidism.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):60-2 doi:10.58347/tml.2025.1726c | Show Introduction Hide Introduction
Dehydroepiandrosterone (DHEA)
The Medical Letter on Drugs and Therapeutics • May 09, 2005 (Issue 1208)
Letter
®
On Drugs and Therapeutics
IN THIS ISSUE
Volume 47 (Issue 1208)
May 9, 2005 ...
Dehydroepiandrosterone (DHEA), an endogenous adrenal steroid, is marketed as a dietary supplement in the US. It is widely promoted to reverse the effects of aging (loss of muscle, memory and libido) and has been used by athletes as a substitute for anabolic steroids. DHEA is banned by the International Olympic Committee, National Collegiate Athletic Association, National Football League and other sports organizations, but it was specifically exempted from becoming a controlled substance in the Anabolic Steroid Control Act of 2004.
Acupuncture
The Medical Letter on Drugs and Therapeutics • May 08, 2006 (Issue 1234)
Letter
®
On Drugs and Therapeutics
IN THIS ISSUE
Volume 48 (Issue 1234)
May 8, 2006 ...
Acupuncture is the practice of inserting fine needles for therapeutic purposes into points on the skin known as acupoints. In traditional Chinese medicine theory, these points arefound along channels that conduct "qi" (pronounced "chee"), or energy. In addition to insertion of needles, acupoints can be stimulated by heat, electrical current or just pressure.
Insulin Detemir (Levemir), a New Long-Acting Insulin
The Medical Letter on Drugs and Therapeutics • Jul 03, 2006 (Issue 1238)
Letter
®
On Drugs and Therapeutics
IN THIS ISSUE
Volume 48 (Issue 1238)
July 3, 2006 ...
Insulin detemir (Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the elimination of the amino acid threonine in position B30 and the addition of a 14-carbon fatty acid chain at position B29. Insulin glargine (Lantus), the first long-acting insulin analog, has been available since 2001 and is usually given once daily.1 NPH insulin is an intermediate-acting basal insulin given twice daily. Basal insulins are usually combined with prandial doses of a rapid-acting...
Golimumab (Simponi) for Inflammatory Arthritis
The Medical Letter on Drugs and Therapeutics • Jul 13, 2009 (Issue 1316)
OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS
The Medical Letter
®
On Drugs ...
Golimumab (Simponi - Centocor), a fully humanized anti-tumor necrosis factor (TNF)-a antibody, has been approved by the FDA for the treatment of: (1) moderate to severe active rheumatoid arthritis (RA) in combination with methotrexate; (2) active psoriatic arthritis (PsA) alone or in combination with methotrexate; and (3) active ankylosing spondylitis (AS).
Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015 (Issue 1463)
The Medical Letter®
on Drugs and Therapeutics
Objective Drug Reviews Since 1959
Volume 57 (Issue ...
The FDA has approved ceftolozane/tazobactam
(Zerbaxa – Cubist), a combination of a new cephalosporin
antibiotic and a beta-lactamase inhibitor, for
intravenous treatment of complicated urinary tract
and intra-abdominal infections in adults.
Concentrated Insulin Glargine (Toujeo) for Diabetes
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
The Medical Letter®
on Drugs and Therapeutics
Objective Drug Reviews Since 1959
Volume 57 (Issue ...
The FDA has approved Toujeo (Sanofi), a more
concentrated form of insulin glargine containing 300
IU/mL compared to the 100 IU/mL in Lantus (Sanofi).
Lantus is nearing the end of its patent protection in the
US, and biosimilars are expected to become available.
Epirubicin for Adjuvant Therapy in Node-Positive Breast Cancer
The Medical Letter on Drugs and Therapeutics • Feb 07, 2000 (Issue 1071)
The Medical Letter
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 Main ...
Epirubicin, an analog of doxorubicin that has been available in Europe and Canada for 15 years, has now been approved by the FDA for adjuvant use after resection of the primary tumor in breast cancer patients with axillary node involvement.